Brief: Turnstone Biologics Reports Positive Initial Data From Phase 1 Trial Of Tidal-01
14/08/2024 21:04
Aug 14 (Reuters) - Turnstone Biologics Corp TSBX.O :
* TURNSTONE BIOLOGICS CORP. REPORTS POSITIVE INITIAL DATA
FROM
PHASE 1 TRIAL OF TIDAL-01 IN METASTATIC COLORECTAL CANCER
* TURNSTONE BIOLOGICS CORP: FAVORABLE TOLERABILITY PROFILE
AND
DEMONSTRATED MANUFACTURING SUCCESS
* TURNSTONE BIOLOGICS CORP - REPORTS FAVORABLE TOLERABILITY
PROFILE FOR TIDAL-01
* TURNSTONE BIOLOGICS CORP - REPORTS 25% ORR AND 50% DCR IN
PHASE
1 TRIAL
Source text for Eikon: ID:nGNX9GZ1K
Further company coverage: TSBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Turnstone Biologics
See all newsBrief: Turnstone Biologics to Be Acquired by XOMA for $0.34/Share Plus Contingent Value Right
U.S. STOCKS ON THE MOVE-Walmart, crypto, banks
Turnstone rises as company cuts job, changes executives
Brief: Turnstone Biologics Sees One-Time Severance-Related Charge Associated With Workforce Reduction To Be About $2.3 Million
Brief: Turnstone Biologics Announces Strategic Restructuring To Prioritize Portfolio And Extend Financial Runway